48 related articles for article (PubMed ID: 17145869)
21. The MUC1 oncoprotein as a functional target: immunotoxin binding to alpha/beta junction mediates cell killing.
Rubinstein DB; Karmely M; Pichinuk E; Ziv R; Benhar I; Feng N; Smorodinsky NI; Wreschner DH
Int J Cancer; 2009 Jan; 124(1):46-54. PubMed ID: 18821582
[TBL] [Abstract][Full Text] [Related]
22. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
23. Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma.
Burton J; Mishina D; Cardillo T; Lew K; Rubin A; Goldenberg DM; Gold DV
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3065s-3072s. PubMed ID: 10541345
[TBL] [Abstract][Full Text] [Related]
24. [Soluble expression of peptide containing MUC1/Y-specific epitope in Escherichia coli and preparation of the antibody].
Zhang LX; Li CH; Sun LY; Wang M; Lu HJ
Sheng Wu Gong Cheng Xue Bao; 2003 May; 19(3):337-42. PubMed ID: 15969018
[TBL] [Abstract][Full Text] [Related]
25. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
26. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells.
Rubinstein DB; Karmely M; Ziv R; Benhar I; Leitner O; Baron S; Katz BZ; Wreschner DH
Cancer Res; 2006 Dec; 66(23):11247-53. PubMed ID: 17145869
[TBL] [Abstract][Full Text] [Related]
27. [New mucin core protein genes and their clinical application].
Imai K
Hokkaido Igaku Zasshi; 1996 Mar; 71(2):139-43. PubMed ID: 8641670
[TBL] [Abstract][Full Text] [Related]
28. Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy.
Madsen CB; Wandall HH; Pedersen AE
Immunopharmacol Immunotoxicol; 2013 Dec; 35(6):649-52. PubMed ID: 24063621
[TBL] [Abstract][Full Text] [Related]
29. Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy.
Zhou D; Xu L; Huang W; Tonn T
Molecules; 2018 May; 23(6):. PubMed ID: 29857542
[TBL] [Abstract][Full Text] [Related]
30. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers.
Albrecht H; Denardo GL; Denardo SJ
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):304-13. PubMed ID: 17464275
[TBL] [Abstract][Full Text] [Related]
31. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996.
Price MR; Rye PD; Petrakou E; Murray A; Brady K; Imai S; Haga S; Kiyozuka Y; Schol D; Meulenbroek MF; Snijdewint FG; von Mensdorff-Pouilly S; Verstraeten RA; Kenemans P; Blockzjil A; Nilsson K; Nilsson O; Reddish M; Suresh MR; Koganty RR; Fortier S; Baronic L; Berg A; Longenecker MB; Hilgers J
Tumour Biol; 1998; 19 Suppl 1():1-20. PubMed ID: 9422084
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma.
Miles DW; Taylor-Papadimitriou J
Pharmacol Ther; 1999 Apr; 82(1):97-106. PubMed ID: 10341360
[TBL] [Abstract][Full Text] [Related]
33. Anti-MUC1 aptamer: A potential opportunity for cancer treatment.
Nabavinia MS; Gholoobi A; Charbgoo F; Nabavinia M; Ramezani M; Abnous K
Med Res Rev; 2017 Nov; 37(6):1518-1539. PubMed ID: 28759115
[TBL] [Abstract][Full Text] [Related]
34. MUC1 and the immunobiology of cancer.
Taylor-Papadimitriou J; Burchell JM; Plunkett T; Graham R; Correa I; Miles D; Smith M
J Mammary Gland Biol Neoplasia; 2002 Apr; 7(2):209-21. PubMed ID: 12463741
[TBL] [Abstract][Full Text] [Related]
35. Anti-mucin monoclonal antibodies.
Xing PX; Apostolopoulos V; Pietersz G; McKenzie IF
Front Biosci; 2001 Oct; 6():D1284-95. PubMed ID: 11578979
[TBL] [Abstract][Full Text] [Related]
36. A review on development of MUC1-based cancer vaccine.
Gao T; Cen Q; Lei H
Biomed Pharmacother; 2020 Dec; 132():110888. PubMed ID: 33113416
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
